Hengrui Medicine has achieved remarkable results in the first half of 2025, with revenue soaring to RMB 15.761 billion, marking a year-on-year increase of 15.88%, and net profit attributable to shareholders reaching RMB 4.450 billion, a year-on-year surge of 29.67%. Both figures set new records. The company has continued to bolster its investment in research and development, with cumulative R&D expenses surpassing RMB 48 billion. Revenue from innovative drugs amounted to RMB 7.570 billion, comprising 55.28% of the company's main business revenue. Furthermore, Hengrui has forged multiple collaborations with multinational pharmaceutical giants such as Merck & Co., Merck KGaA, and GSK, with the transaction value with GSK setting a new benchmark for domestic BD deals. During the first half of the year, the company advanced 15 self-developed innovative molecules to the clinical stage and secured marketing approvals for 6 Class 1 innovative drugs, bringing the total number of approved drugs to 23. Hengrui's innovative drug research and development achievements are swiftly transitioning, and the company has made notable strides in its internationalization efforts.